// App-Quantinova.ai

1431 : Impact of Tofacitinib on Fracture Risk in Rheumatoid Arthritis

Researchers

Presenter

  • Karen E Hansen

Principal Investigators

  • Mahta Mortezavi

  • Edward Nagy

  • Cunshan Wang

  • Carol A Connell

  • Zaher Radi

  • Heather J Litman

  • Giovanni Adami

  • Maurizio Rossini

Medical Centers

  • Pfizer, Groton, CT

  • Pfizer Inc, New York, NY

  • Unit of Rheumatology, Department of Medicine,, University of Verona, Verona, Italy

  • Division of Nephrology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI

  • CorEvitas LLC, Waltham, MA, USA

  • Pfizer Inc., Tadworth, United Kingdom

Locations

  • United States

  • United Kingdom

  • Italy

Companies

  • Pfizer Inc.

  • PharmAbcine Inc.

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Rheumatoid arthritis

Biomarkers

  • Tumor necrosis factor

Drug/Treatment

  • Tasocitinib

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Open Label

  • Observational

  • Multicenteric

  • Prospective

  • Controlled

  • Cohort

Phase

  • III

Study Id's

  • NCT02092467

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved